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Background: Overexpression of the high-mobility group, HMG I/Y, family of
chromatin oncoproteins has been implicated as a clinical diagnostic marker for
both neoplastic cellular transformation and increased metastatic potential of
several human cancers. These minor groove DNA-binding oncoproteins are thus
an attractive target for anti-tumor chemotherapy. FR900482 represents a new
class of anti-tumor agents that bind to the minor groove of DNA and exhibit
greatly reduced host toxicity compared to the structurally related mitomycin C
class of anti-tumor drugs. We report covalent cross-linking of DNA to HMG I/Y by
FR900482 in vivo which represents the ¢rst example of a covalent DNA^drug^
protein cross-link with a minor groove-binding oncoprotein and a potential novel
mechanism through which these compounds exert their anti-tumor activity.
Results: Using a modi¢ed chromatin immunoprecipitation procedure, fragments
of DNA that have been covalently cross-linked by FR900482 to HMG I/Y proteins
in vivo were polymerase chain reaction-ampli¢ed, isolated and characterized. The
nuclear samples from control cells were devoid of DNA fragments whereas the
nuclear samples from cells treated with FR900482 contained DNA fragments
which were cross-linked by the drug to the minor groove-binding HMG I/Y proteins
in vivo. Additional control experiments established that the drug also cross-linked
other non-oncogenic minor groove-binding proteins (HMG-1 and HMG-2) but did
not cross-link major groove-binding proteins (Elf-1 and NFUB) in vivo. Our results
are the ¢rst demonstration that FR900482 cross-links a number of minor groove-
binding proteins in vivo and suggests that the cross-linking of the HMG I/Y
oncoproteins may participate in the mode of ef¢cacy as a chemotherapeutic
agent.
Conclusions: We have illustrated that the FR class of anti-tumor antibiotics,
represented in this study by FR900482, is able to produce covalent cross-links
between the HMG I/Y oncoproteins and DNA in vivo. The ability of this class of
compounds to cross-link the HMG I/Y proteins in the minor groove of DNA
represents the ¢rst demonstration of drug-induced cross-linking of a speci¢c
cancer-related protein to DNA in living cells. We have also demonstrated that
FR900482 cross-links other minor groove-binding proteins (HMG-1 and HMG-2 in
the present study) in vivo; however, since HMG I/Y is the only minor groove-
binding oncoprotein presently known, it is possible that these non-histone
chromatin proteins are among the important in vivo targets of this family of drugs.
These compounds have already been assessed as representing a compelling
clinical replacement for mitomycin C due to their greatly reduced host toxicity and
superior DNA interstrand cross-linking ef¢cacy. The capacity of FR900482 to
cross-link the HMG I/Y oncoprotein with nuclear DNA in vivo potentially
represents a signi¢cant elucidation of the anti-tumor ef¢cacy of this family of
anticancer agents.
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Introduction
The mammalian high-mobility group, HMG I/Y, non-his-
tone chromosomal proteins are founding members of a new
class of gene regulatory proteins called ‘architectural tran-
scription factors’ that function by recognizing and altering
the structure of DNA and chromatin substrates (reviewed
in [1^3]). The HMG I/Y protein family consists of three
known members: HMG-I and HMG-Y, alternatively
spliced protein variants encoded for by a single gene,
and HMGI-C, the product of a separate locus [4^8]. The
CHBIOL 27 2-10-00 Cyaan Magenta Geel Zwart
Research Paper 805
HMG I/Y proteins are distinguished from other architec-
tural transcription factors by their ability to preferentially
bind to the minor groove of AWT-rich regions via novel
DNA-binding motifs called AWT hooks (Figure 1) [9,10].
The HMG I/Y proteins have been implicated in the in
vivo transcriptional regulation of numerous mammalian
genes [1^3], many of which are associated with the im-
mune system and cell growth [11^16], through participa-
tion in the formation of stereo-speci¢c, multi-protein com-
plexes called ‘enhanceosomes’ on gene promoter/enhancer
regions.
Arti¢cial overexpression of HMG I/Y proteins leads to can-
cerous transformation of cells (Li and Reeves; unpublished
data) and elevated levels of these proteins are, therefore, a
consistent feature of many different types of tumors. In
fact, overexpression of the HMG I/Y proteins has been
suggested to be a diagnostic clinical marker for both neo-
plastic transformation and increased metastatic potential of
cancer cells (reviewed in [17^20]). In particular, it has been
demonstrated that HMG I/Y proteins are over-expressed in
human tumors of the prostate, colon, thyroid and breast,
among other tissues. This manifest involvement of HMG
I/Y overexpression in neoplasia suggests that drugs that can
abrogate the functional integrity of these proteins when
bound to DNA may have improved ef¢cacy for tumor cells.
It has been demonstrated that the FR family of anti-tumor
antibiotics (FR900482 (1), FR66979 (2), FK973 (3),
FR70496 (5) and FK317 (4), which is currently in Phase
II clinical trials in Japan; Figure 2) undergo reductive acti-
vation in vitro to form the reactive mitosene derivative 9
(Figure 3), which preferentially cross-links duplex DNA at
50CpG3
0
steps [21^25]. The mechanism of reductive activa-
tion involves the thiol-mediated two-electron reduction of
the N^O bond [25] in the presence of trace Fe(II) [26,27]
generating the transient ketone 7 that rapidly cyclizes to
the carbinolamine 8. Expulsion of water has been inferred
as the rate-determining step en route to the electrophilic
mitosene 9 [26,27]. Therefore, FR900482 and the structur-
ally related mitomycin C [28] are naturally occurring clever
‘pro-drugs’ that must be reductively activated in vivo to
expose the highly reactive electrophilic mitosene deriva-
tives that are responsible for the biological activity dis-
played by these substances [24,26,27].
Results and discussion
Early efforts establishing the minor groove speci¢city of
the FR900482 class of agents suggest that the minor
groove-binding HMG I/Y motif might represent a relevant
peptide target for these drugs. We have recently reported
the capacity of FR66979 to covalently cross-link the bind-
ing domain peptide of the non-histone chromosomal DNA-
Figure 1. Structure of the DNA-binding
domain II of human HMG I/Y bound to
DNA showing the association of the
conserved AWT hook protruding deeply into
the minor groove [10].
Figure 2. Structures of the clinically
signi¢cant FR class of compounds (1^5)
and mitomycin C (6).
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binding proteins of the HMG I/Y class in vitro [29]. This
was further supported by modeling studies in which one of
the two palindromic arginine moieties (of PRGRP run)
place a guanidine nitrogen proximal (within 2^3 Aî ) to
the mitosene C10 position of a FR66979 monoalkylated
deoxyguanosine residue abutting the binding domain rec-
ognition sequence 5P AAATTT 3P. This suggested that a
sequence bearing the FR66979 alkylation ‘hot-spot’
50CpG3
0
to the 5P side of 5P AATT 3P would result in a
high probability for the reaction between an essential argi-
nine and the C10 center of the mitosene. As a signi¢cant
extension, we now report the ¢rst example of a small or-
ganic anti-tumor drug that forms an in vivo covalent cross-
link to an entire DNA-binding protein of relevance to can-
cer cells. The ability of these anti-tumor antibiotics to
cross-link the HMG I/Y protein with nuclear DNA in living
cells suggests a mechanism for anti-tumor ef¢cacy by ab-
rogating the functional integrity of these oncoproteins.
Determination of in vivo cytotoxicity of FR900482
Human Jurkat T-leukemia cells were chosen for drug tox-
icity and cross-linking studies because they contain high
endogenous levels of the HMG I/Y proteins and also be-
cause they can be induced to express speci¢c cytokine
genes, such as interleukin-2 (IL-2) and the K subunit of
the IL-2 receptor (IL-2RK), whose transcriptional expres-
sion in vivo is regulated by these proteins [11^16,30]. Jur-
kat cells (3U106) were exposed for 24, 48 and 72 h to
varying concentrations (1.0, 1.5 and 2.0 WM) of FR900482
and the remaining viable cells were counted in each cul-
ture using a hemocytometer. Twenty-four hours after the
addition of FR900482, the cells showed signi¢cant inhibi-
tion of cell proliferation at the lowest concentration of the
drug, with death occurring at high concentrations (Figure
4).
The viability of all cells in each culture treated with
FR900482 was assessed by exclusion of the dye Trypan
blue (2%). Staining of cells by the blue dye was indicative
of cell death. Throughout the 72 h period, most cells
treated with 1.0 WM drug remained viable (s 90%) but
were non-proliferating. In contrast, after 48 h cells that
had been treated with either 1.5 or 2.0 WM concentrations
of the drug showed signi¢cant decreases in viability
(I90%). These results indicate that at low concentrations
of FR900482, cells remain alive but quiescent while at
higher drug concentrations overt toxicity and death occurs.
Determination of the mode of cell death: necrosis versus
apoptosis
We determined that cell death mediated by FR900482 was
due to necrosis rather than apoptosis. Nuclear DNA was
isolated from cells after 24 and 48 h of drug exposure and
analyzed on a 2% agarose gel for DNA fragmentation into a
nucleosome ladder that is characteristic of apoptosis. DNA
fragmentation was also assessed using the commercial TU-
NEL assay. Neither of these assay procedures detected
Figure 3. Mechanism of reductive activation and DNA interstrand cross-link formation of FR900482.
Figure 4. Cell growth inhibition caused by various concentrations
of FR900482 over 0, 24, 48 and 72 h time periods, respectively.
The inset shows a magni¢ed view of the results from the drug-
treated cells. Error bars are þ S.D.
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signi¢cant DNA fragmentation in cells exposed to
FR900482 although treatment of the cells with the drug
anisomycin, which is known to induce apoptosis, did result
in signi¢cant DNA fragmentation (Figure 5). In addition,
histochemical staining failed to detect gross nuclear frag-
mentation indicative of apoptosis but did show extensive
cytoplasm loss and considerable nuclear condensation,
characteristics of necrosis, in the drug-treated cells (Figure
5). We therefore conclude that the toxicity of FR900482 is
likely the result of induction of necrotic cellular death.
HMG I/Y^drug^DNA cross-link formation in vivo
For cross-linking studies, Jurkat cells were treated for 6^24
h with 1.0 WM of FR900482 or with 1% formaldehyde for
60 min. The chromatin was subsequently isolated, sheared
by sonication and the cross-linked HMG I/Y protein^DNA
adducts reacted with a speci¢c anti-HMG I/Y antibody.
The resulting antibody^protein^DNA complexes were iso-
lated on protein A Sepharose beads as previously described
[31^33]. The protein A Sepharose beads non-covalently
bind to the speci¢c anti-HMG I/Y antibody, thus enabling
the isolation of any potential cross-linked HMG I/Y pro-
tein^DNA adducts in the cells. In this modi¢ed chromatin
immunoprecipitation (CHIP) procedure, fragments of
DNA that have been covalently cross-linked by
FR900482 to HMG I/Y proteins in vivo are thus tightly
bound to the Sepharose beads whereas fragments of
DNA not cross-linked to these proteins are eluted from
the beads. This immunofractionation procedure ef¢ciently
differentiates the chromatin isolated from control cells (not
treated with FR900482) from the chromatin isolated from
the experimental drug-treated cells. Thus, the nuclear
samples from control cells attached to the beads should
be devoid of DNA fragments whereas the nuclear samples
attached to the beads from the experimental cells should
contain DNA fragments speci¢cally cross-linked by the
drug to the HMG I/Y proteins in vivo. The DNA frag-
ments bound to the Sepharose beads from control and
experimental drug-treated cells were isolated and screened
for speci¢c DNA sequences postulated to be bound in vivo
by the HMG I/Y protein and were ampli¢ed by polymerase
chain reaction (PCR).
The DNA sequences chosen for investigation were the
highly repetitive, AWT-rich Alu sequences which are
present in approximately 500 000 copies in the human ge-
nome [34,35] and the unique sequence promoter regions of
the human IL-2 and IL-2RK genes which bind, and are
Figure 5. Histochemical staining of Jurkat
cells analyzed by a £uorescence
microscope. A: Control cells (20U);
B: cells treated with anisomycin to induce
DNA fragmentation as seen in apoptosis
(20U); C: cells treated with 1.0 WM
FR900482 for 24 h (20U). Histochemical
staining of Jurkat cells using hematoxylin
and eosin B. Cells were treated with 1 WM
FR900482 for 0 (D), 6 (E), 12 (F), 24 (G),
36 (H) and 48 (I) h. The nucleus stained
by hematoxylin is shown in dark red while
the cytoplasm stained by eosin B is pink.
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regulated by, the HMG I/Y in T lymphocytes in vivo [11^
16,30].
PCR primers were designed to amplify DNA fragments of
both the repetitive Alu repeat sequences and the unique
IL-2 and IL-2RK promoter sequences, all of which contain
numerous AWT-rich, potential HMG I/Y binding sites. In
the case of the IL-2 [30] and the IL-2RK [15] promoters,
the binding sites for HMG I/Y have been footprinted in
vitro and are indicated by the bold, underlined letters in
Figure 7. All three of these substrates (i.e. Alu, IL-2 and
IL-2RK) have several deoxyguanosine residues, which are
well known potential drug monoalkylation sites [26^27,29],
adjacent to one or more of the AWT-rich stretches, therefore
providing potential protein^DNA cross-linking sites. It
should be noted, however, that the ‘exact’ in vivo drug
alkylation sites have not yet been characterized for any
of these substrates.
Figure 6 shows the results of PCR ampli¢cations of DNA
fragments present in immunoprecipitates after 24 h of drug
treatment using primers for the IL-2 promoter (Figure 6A)
and the IL-2RK promoter (Figure 6B). This ¢gure illus-
trates the presence of ampli¢ed DNA products that re-
sulted from the formation of the drug-induced HMG I/
Y^DNA cross-links in the experimental, but not the con-
trol, cells. Similar results were obtained with the Alu prim-
ers (data not shown). The presence of these DNA frag-
ments in the experimental cells is indicative of the
formation of HMG I/Y^drug^DNA covalent cross-links in
vivo during the period of drug exposure. As seen in Figure
6A,B, none of the control (i.e. non-drug treated) cells pro-
duced PCR products with anti-HMG I/Y, as expected. In
Figure 6. PCR of pellet and supernatant of immunoprecipitated
DNA-protein crosslinks. In all panels, the PCR product is the
upper band, while the lower band contains primer dimers.
A: CHIP assay using HMG I/Y serum. PCR performed using
primers designed for the IL-2 gene promoter [15]. Lanes 1^3 are
PCR results from the supernatants and lanes 4^6 are PCR
results from the immunoprecipitated pellets. Lanes 1 and 4 are
cells treated with 1% formaldehyde; lanes 2 and 5 are cells
treated with 1 WM FR900482; and lanes 3 and 6, are the cells left
untreated. B: CHIP assay using HMG I/Y serum. PCR was done
using primers designed for a IL-2RK gene promoter. Lanes 1^3
are PCR results from the supernatants and lanes 4^6 PCR
results from the immunoprecipitated pellets. Lanes 1 and 4 are
cells treated with 1 WM FR900482; lanes 2 and 5 are cells left
untreated; and lanes 3 and 6 are cells treated with 1%
formaldehyde. C: CHIP assay using Elf-1 antibodies. PCR
performed using primers designed for the IL-2R K gene promoter.
Lanes 1^3 are PCR results from the supernatants and lanes 4^6
PCR results from the immunoprecipitated pellets. Lanes 1 and 4
are cells treated with 1% formaldehyde; lanes 2 and 5 are cells
treated with 1 WM FR900482; and lanes 3 and 6, cells left
untreated.
Figure 7. A: Sequence of the cross-linked product PCR ampli¢ed
with primers designed for the IL-2 promoter (GenBank accession
No. J006884). B: Sequence of the cross-linked product PCR
ampli¢ed with primers designed for the IL-2RK promoter
(GenBank accession No. M15864). The bold, underlined letters
indicate AWT-rich sequences footprinted in vitro by the HMG I/Y
proteins on the IL-2 promoter [30] and the IL-2RK promoter [15].
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addition, control cells did not produce PCR products with
preimmune sera (data not shown). Figure 6 also shows that
all of the samples contained DNA, as PCR on the super-
natants collected after the protein A Sepharose step did
indeed, as expected, show the same size bands in all lanes.
On the other hand, DNA fragments of the sizes predicted
(V300 bp) for the promoter regions of the IL-2 and the
IL-2RK genes were obtained in the speci¢c PCR ampli¢-
cation reactions employing anti-HMG I/Y (but not preim-
mune) immunoprecipitates obtained from the drug-treated
experimental cells. These bands could be detected as soon
as 6 h after addition of drug to the cells (data not shown).
As a positive control, drug-free cells that had been ¢xed
with the non-speci¢c cross-linking agent formaldehyde also
rendered similar PCR products (Figure 6). These results
are clearly consistent with the in vivo covalent cross-link-
ing of HMG I/Y proteins to the nuclear DNA of Jurkat
cells by FR900482.
FR900482 cross-links other minor groove-binding proteins
to DNA in vivo
Since it is known that FR900482 binds in the minor
groove, it is then important to determine if FR900482 is
speci¢c for HMG I/Y or if it cross-links other minor groove-
binding proteins as well. Immunoprecipitation experiments
were therefore performed with two other minor groove-
binding proteins, HMG-1 and HMG-2. Although HMG-1
and HMG-2 are also members of the high-mobility class of
chromatin proteins they are unrelated structurally to the
HMG I/Y proteins and exhibit no DNA sequence binding
speci¢city (reviewed in [2]). HMG-1 monoclonal antibod-
ies or HMG-2 serum were used in the CHIP assay and
PCR was done using primers designed for the Alu repeat
sequence. HMG-1 and HMG-2 were cross-linked by both
formaldehyde and FR900482 to DNA (data not shown).
These results show that FR900482 is not speci¢c for
HMG I/Y, but cross-links other minor groove-binding pro-
teins of which there are only a few known members, such
as HMG I/Y, HMG-1, HMG-2 and others. However, HMG
I/Y is the only known minor groove-binding oncoprotein so
FR900482’s ability to cross-link this nuclear protein may
represent a new mechanism of action for anti-tumor drugs.
FR900482 does not non-speci¢cally cross-link proteins to
the DNA major groove in vivo
Since both FR900482 and HMG I/Y are known to bind
speci¢cally in the minor groove of DNA, an important
control for the modi¢ed CHIP assays described above is
to demonstrate that the drug does not non-speci¢cally
cross-link proteins in the major groove. Immunoprecipita-
tion experiments were therefore, repeated using antibodies
against the T lymphocyte-speci¢c protein Elf-1 which is
present in Jurkat cells and binds to the major groove of
AWT-rich sequences in the promoter of the IL-2RK gene
overlapping a site bound and regulated by the HMG I/Y
protein in vivo [11^16]. Two independent immunoprecipi-
tation experiments show that Elf-1 is not cross-linked to
DNA with FR900482 (e.g. lane 5, Figure 6C) while, in
control experiments, Elf-1 is cross-linked to the major
groove of the IL-2RK gene promoter by the non-speci¢c
reagent formaldehyde (lane 4, Figure 6C). In addition,
antibodies against NF-UB (p50), a non-T lymphocyte re-
stricted major groove-binding transcription factor that binds
the promoter region of IL-2RK, were used in the immu-
noprecipitation experiment. These experiments show that
NF-UB is not cross-linked to the DNA by FR900482, but
is cross-linked by formaldehyde (data not shown). These
results demonstrate that FR900482 cross-linking of pro-
teins to DNA has speci¢city for the minor groove.
Characterization of DNA cross-linked to HMG I/Y by
FR900482 in vivo
The PCR ampli¢ed products from the anti-HMG I/Y im-
munoprecipitates isolated from drug-treated cells were ex-
cized from gels and subcloned into the pGEM T-Easy
vector and sequenced. Figure 7 shows the sequences of
the DNA obtained from these CHIP assays of drug-treated
cells. A Blast search revealed that they were from the ex-
pected human IL-2 and IL-2RK gene promoter regions.
Signi¢cance
In conclusion, we have illustrated that the FR class of anti-
tumor antibiotics, represented in this study by FR900482,
are able to produce covalent cross-links between the HMG
I/Y proteins and DNA in vivo. The ability of these com-
pounds to cross-link the HMG I/Y oncoproteins in the
minor groove of DNA represents, to our knowledge, the
¢rst demonstration of drug-induced cross-linking of a spe-
ci¢c cancer-related protein to DNA in living cells. These
results do not exclude the potential in vivo cross-link for-
mation with other minor groove-binding proteins that are
not directly related to neoplastically transformed cells. In-
deed, we have demonstrated that other minor groove-bind-
ing proteins such as HMG-1 and HMG-2 are also cross-
linked in cells by this agent. However, the capacity of
FR900482 to cross-link the HMG I/Y proteins, the only
known minor groove-binding oncoproteins, with nuclear
DNA in vivo represents a potentially novel mechanism
that might contribute to the anti-tumor ef¢cacy of these
compounds by abrogating the functional integrity of these
oncoproteins. These compounds have already been as-
sessed as representing a compelling clinical replacement
for mitomycin C due to their greatly reduced host toxicity
and superior DNA interstrand cross-linking ef¢cacy
[23,24,36^38]. Based on these observations, it is reasonable
to anticipate that other drugs that covalently cross-link
DNA in the minor groove might also form covalent adducts
with the HMG I/Y proteins. Efforts to investigate the gen-
erality of these lesions are under study in these laboratories
and will be reported in due course.
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Materials and methods
Human Jurkat T-leukemia cells (clone E6-1; American Type Culture
Collection, Rockville, MD, USA) were grown in RPMI-1640 Media (Gib-
co-BRL, Rockville, MD, USA) supplemented with 10% fetal bovine se-
rum, penicillin (614 Wg/ml, Sigma, St. Louis, MO, USA), streptomycin (10
Wg/ml, Sigma, St. Louis, MO, USA) and HEPES buffer, pH 7.2 at 37³C,
5% CO2.
Determination of the mode of cell death
Jurkat cells (1U107 cells) were treated with anisomycin (2 Wg/ml; Sig-
ma, St. Louis, MO, USA) for 5 h, and FR900482 for 24 and 48 h at
37³C, 5% CO2. To test for nucleosome fragmentation, the DNA was
isolated and analyzed on a 2% agarose gel at 100 V for 90 min. For
TUNEL assays, the kit Apoptosis Detection System, Fluorescein (Prom-
ega, Madison, WI, USA) was used. Brie£y, Jurkat cells (3U107 cells)
were spread on a poly-L-lysine slide (Sigma, St. Louis, MO, USA), the
cells were washed in phosphate-buffered saline (PBS), ¢xed with 4%
paraformaldehyde and permeabilized with 0.2% Triton X-100. The cells
were incubated with 50 WM £uorescein-12-dUTP, equilibration buffer
(supplied with kit) and terminal deoxynucleotidyl transferase (TdT) for
1 h at 37³C. The reaction was stopped by washing the cells in 2U SSC
followed by washes in PBS. The cells were counterstained using
1 mg/ml propidium iodine and washed in dH2O. The cells were analyzed
using a £uorescence microscope. Cells that displayed green £uores-
cence were indicative of DNA fragmentation due to labeling by the
£uorescein-12-dUTP by TdT. Histochemical staining of cells was done
using Gill's hematoxylin and counterstained in eosin B.
HMG I/Y^drug^DNA cross-link formation in vivo
Jurkat cells (3U106) were treated with either 1 WM FR900482 for 6, 12,
24, 36 and 48 h at 37³C, 5% CO2 or 1% formaldehyde for 60 min at
4³C. Glycine (0.125 M) was added to the formaldehyde cross-linked
cells to stop the cross-linking reaction. The nuclei from the treated
and untreated Jurkat cells were isolated using a buffer containing 0.34
M sucrose, 0.2 M KCl, 100 mM EGTA, 500 mM EDTA, 494 mM sper-
mine, 689 mM spermidine, 10 mM HEPES and 5% NP-40. The nuclei
were washed in the same buffer without NP-40 and redissolved in TE
buffer. The nuclei were fragmented by sonication for 10 min on ice.
Following sonication, SDS (1%) was added, the DNA was extracted
with phenol:chloroform:isoamyl alcohol (25:24:1) and ethanol precipi-
tated. The DNA was subsequently redissolved in PBS and sonicated
for a further 2 min on ice. Protease inhibitors (PMSF, 200 Wg/Wl; apro-
tinin, 60 Wg/Wl) were added along with HMG I/Y serum at a ratio of 50:1
or 100:1, HMG-1 monoclonal antibody (10:1), HMG-2 serum (50:1), Elf-1
(50:1 or 100:1, Santa Cruz Biotechnology) or NF-UB p50 (50:1 or 100:1
ratio, Santa Cruz Biotechnology). The protease inhibitors and either
HMG I/Y (50:1) serum, HMG-1 monoclonal antibody, HMG-2 serum,
Elf-1 antibody, NF-UB antibody or preimmune serum (50:1) were also
added to untreated Jurkat cells. The reaction was allowed to proceed
overnight at 4³C, after which protein A Sepharose beads were added
(1:10 ratio) and the mixture was incubated for 90 min at 4³C. The DNA^
protein cross-link was subsequently isolated by centrifugation and col-
lection of the protein A Sepharose beads. The beads were resuspended
in PBS and SDS (0.1%) and proteinase K (5 Wg) was added. The
samples were allowed to incubate for 30 min at 37³C and the samples
were extracted with a phenol:chloroform:isoamyl alcohol (25:24:1) mix-
ture. PCR primer sequences for human Alu sequences (accession num-
ber: U73024) are Alu1 (sense): 5P GCCCATGCCCTGTTGAGCTT 3P (bp
3982^4002) and Alu2 (anti-sense): 5P GGCCTGTGAATTCAGGCCTA 3P
(bp 4423^4463). PCR primer sequences for the human IL-2 gene pro-
moter (accession number: J006884) are IL-2-1 (sense): 5P TAATGTAA-
CAAAGAGGGATTTCACC 3P (bp 193^217) and IL-2-2 (anti-sense): 5P
GGAGTTGAGGTTACTGTGAGTAGTC 3P (bp 450^427). PCR primer
sequences for the human IL-2RK promoter (accession number:
M15864) are IL-2RK-1 5P CCAGCCCACACCTCCAGCAA 3P (bp
1052^1071) and IL-2RK-2 5P CCTCTTTTTGGCATCGCGCCG 3P (bp
1306^1327). PCR conditions were 0.5 mM dNTPs, 2 WM primers,
4 mM MgCl2 (for IL-2 and IL-2RK primers) or 6 mM MgCl2 (Alu primers),
100 mM Tris, pH 9.0, 50 mM KCl, 1% Triton X-100, 1 mM DTT. Taq
polymerase was used with 30 cycles of 96³C for 30 s, 52³C for 30 s (Alu
and IL-2 primers) or 60³C for 30 s (IL-2RK) and 72³C for 45 s. The PCR
samples were then run on a 1% agarose gel. For the major groove
cross-link experiments involving Elf-1 and NF-UB, Jurkat cells (1U107)
were treated with PMA (10 Wg/ml) and ConA (10 ng/ml) for 6 h followed
by the addition of FR900482 for 12 h or 1% formaldehyde for 1 h. The
samples were then processed as for the reactions with HMG I/Y with the
exception of using Elf-1 antibodies or NF-UB instead of the HMG I/Y
serum.
Sequencing of PCR products
Gel slices were excized using GenElute columns (Sigma, St. Louis, MO,
USA) and cloned using the T/A cloning kit and pGem-T-Easy vector
(Promega, Madison, WI, USA). The resulting plasmid was transformed
into Dh5K strain of Escherichia coli and selected on Luria broth (LB)^
ampicillin^IPTG^X-Gal plates. Positive clones were grown overnight in
LB^ampicillin and the plasmids were isolated. The sequencing of plas-
mids was done using a PE Applied Biosystems ABI Prism 377 DNA
sequencer utilizing the Big Dye Terminator Cycle sequencing Kit (Per-
kin-Elmer, Norwalk, CT, USA).
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